Drug treatment may benefit only select group of patients with glioblastoma

the ONA take:

Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas. They found that the drug does inhibit proteins that promote tumor growth; however, it also inhibits proteins that protect against cancer, a finding that negates any benefit of using the drug for patients with glioblastoma.

Findings from the researchers at Mayo Clinic, who conducted one of the clinical trials, suggest that pretesting glioblastoma biopsies may help identify those patients who will benefit from treatment with dasatinib. The drug is a general Src-family kinase (SFK) inhibitor.

The researchers teased apart the effect on individual Src family members (Src, Fyn, Yes, and Lyn). They found that dasatinib inhibited Src, Fyn, and Yes, which reduced growth and migration. It also inhibited Lyn, which protects against cancer growth.

The researchers also found that tumors express all members of the Src family differently, and expression of Yes and Lyn differed among tumors.

Although further testing is needed, the findings suggest that some patients may derive benefit from treatment with dasatinib, in particular those whose tumors express Yes, but not Lyn.

Economic burden of cancer does not stop after treatment
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs